Trial of Two Central Venous Catheter (CVC) Flushing Schemes in Pediatric Hematology and Oncology Patients

Trial of Two Central Venous Catheter (CVC) Flushing Schemes in Pediatric Hematology and Oncology Patients
This study has been terminated.
( Poor patient accrual )

First Received on April 27, 2011.  
Last Updated on May 29, 2012  
History of Changes
Sponsor: Alberta Children’s Hospital
Collaborator: Stollery Children’s Hospital
Information provided by (Responsible Party): Martin Campbell, Alberta Children’s Hospital Identifier: NCT01343680

The purpose of this study is to determine whether flushing Central Venous Catheters (CVCs) with Normal saline once per week is not inferior to flushing with 10U/ml heparin 3 times per week, in preventing CVC occlusions.

Condition Intervention Phase
Childhood Cancer
Aplastic Anemia
Metabolic Disorders
Drug: Heparin
Drug: Normal saline
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Crossover Assignment
Masking: Open Label
Primary Purpose: Prevention
Official Title: A Randomized Controlled Crossover Trial of Two Different Central Venous Catheter Flushing Schemes in Pediatric Hematology and Oncology Patients in Alberta, Canada

Resource links provided by NLM:

Further study details as provided by Alberta Children’s Hospital:

Primary Outcome Measures:

  • Occlusion rate [ Time Frame: 6 months ] [ Designated as safety issue: No ]

Secondary Outcome Measures:

  • Complication rate [ Time Frame: 6 months ] [ Designated as safety issue: Yes ]

Enrollment: 2
Study Start Date: April 2011
Study Completion Date: May 2012
Primary Completion Date: May 2012 (Final data collection date for primary outcome measure)


Assigned Interventions
Active Comparator: 10U/l heparin Drug: Heparin

5ml 10 units/ml IV heparin 3 times per week
Experimental: normal saline Drug: Normal saline

10ml normal saline IV weekly

Detailed Description:

Tunneled central venous catheters (CVCs) are now used routinely in pediatric hematology and oncology patients. Flushing with heparin solution is routinely recommended to prevent occlusion of long term CVCs, although the concentration of heparin used, and frequency of its use varies between centres. Once weekly Normal saline is also used successfully in some pediatric enters. There is little evidence to support one method over the other.

The investigators have designed a randomised crossover trial to directly compare once weekly Normal saline flushing with 3 times per week 10U/ml heparin flushing, to determine whether Normal saline is not inferior to heparin.


Ages Eligible for Study:   up to 17 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria

  • Diagnosis of any malignant or nonmalignant disease that requires a single lumen Broviac or double lumen Hickman-type CVC for the purpose of chemotherapy, blood product support or hematopoietic stem cell transplantation.
  • CVC is planned to remain in situ for 6 months from study entry

Exclusion Criteria:

  • Thrombophilia (e.g. Factor V Leiden mutation, antiphospholipid syndrome) or previous thrombosis requiring anticoagulation (e.g. enoxaparin, unfractionated heparin)
  • Bleeding disorder (e.g. von Willebrand’s disease, hemophilia)
  • Previous CVC that was removed due to any complication
  Contacts and Locations

Please refer to this study by its identifier: NCT01343680

Canada, Alberta
Alberta Children’s Hospital
Calgary, Alberta, Canada, T3B6A8
Stollery Children’s Hospital
Edmonton, Alberta, Canada
Sponsors and Collaborators
Alberta Children’s Hospital
Stollery Children’s Hospital
Principal Investigator: Martin A Campbell, MBBS FRACP Alberta Children’s Hospital
  More Information

No publications provided

Responsible Party: Martin Campbell, Paediatric Oncologist, Alberta Children’s Hospital Identifier: NCT01343680    
History of Changes
Other Study ID Numbers: ACH23736
Study First Received: April 27, 2011
Last Updated: May 29, 2012
Health Authority: Canada: Ethics Review Committee

Additional relevant MeSH terms:

Anemia, Aplastic
Metabolic Diseases
Hematologic Diseases
Bone Marrow Diseases
Signs and Symptoms
Calcium heparin
Hematologic Agents
Therapeutic Uses
Pharmacologic Actions
Fibrinolytic Agents
Fibrin Modulating Agents
Molecular Mechanisms of Pharmacological Action
Cardiovascular Agents processed this record on August 21, 2012

Leave a Reply

You can use these HTML tags

<a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <s> <strike> <strong>




3 × three =